Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers at University of Tsukuba uncover how stratifin causes lung adenocarcinoma to emerge, identifying two drugs with other clinical uses that could be applied effectively in this disease. The study's findings raise hopes for more powerful treatment tools and value drug repositioning as a potential solution.
Researchers have found a pair of old drugs that can disrupt disease-causing pathways in triple negative breast cancer. Metformin and heme, previously used to treat diabetes and porphyria, were tested in mice and produced encouraging results when combined.
Researchers at The Wistar Institute have developed a drug candidate for EBV-associated cancers, inhibiting tumor growth in preclinical models. Pharmacological inhibition of EBNA1 had profound effects on gene expression, decreasing EBV DNA copy number and suppressing tumor-promoting pathways.
Researchers created metallocorrole/protein nanoparticles that can both survive longer in the body and better snipe disease targets. The theranostics have huge chemotherapeutic potential, potentially shortening treatment duration and diminishing side effects for cancer patients.
A new study by Boston University School of Public Health evaluates the Novartis Access program in Kenya, demonstrating that robust, 'gold standard' methods can be used to assess major pharmaceutical companies' access programs. The study found that the program significantly increased availability of two medicines in health facilities bu...
UC San Diego Health, Ochsner Health System, Sutter Health and Stanford Health Care developed diverse models of care incorporating patient-centered technologies with measurable outcomes. Technology improved medication adherence for hypertension and diabetes, reduced distress in cancer patients, and enhanced patient engagement.
Researchers identified S15 as a major immune suppressor in B7-H1-negative tumors resistant to current anti-PD therapies. A first-in-human Phase 1/2 clinical trial is underway for NC318, a monoclonal antibody targeting S15.
Despite the risks, many health care workers do not use recommended personal protective equipment when handling chemotherapy. A study from Michigan Medicine found that nurses who reported handling hazardous drugs had twice the risk of reproductive problems.
Ugur Sahin received the 2019 German Cancer Award for his pioneering research on individualized cancer immunotherapies. He is developing technologies to identify and exploit unique cancer characteristics to guide the immune system against specific tumors.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Researchers at U of T Engineering created a 3D hydrogel to mimic lung cancer environments, selectively allowing cancer cells to invade. This technology enables rapid screening of hundreds of potential drugs for their ability to fight invasive cancers.
Researchers at UCLA have developed a method to screen hundreds of drugs in patients' own cells, creating miniature tumor organoids. This approach can help identify effective treatments for rare and hard-to-treat cancers, and could guide treatment decisions.
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
A clinical trial found sacituzumab govitecan produced a significant treatment response in patients with difficult-to-treat metastatic triple-negative breast cancer, outperforming standard chemotherapy. The drug showed manageable side effects and improved treatment duration.
A new 'smart drug', sacituzumab govitecan, has shown significant tumor shrinkage and improved patient outcomes in a clinical trial for women with metastatic triple-negative breast cancer. The treatment resulted in better response rates and longer overall survival compared to traditional therapies.
Researchers at Johns Hopkins Medicine have discovered a new compound called rapadocin that may prevent reperfusion injury, a tissue-damaging complication of surgery. The compound was found to block the activity of a chemical pathway associated with reperfusion injuries, reducing markers of kidney damage in mice.
The Mark Foundation has selected 14 new ASPIRE Award winners, funding high-risk, high-reward cancer research projects across the US and internationally. These projects focus on early cancer detection, immunotherapy, tumor microenvironment, and more, with the potential to advance cancer medicine.
A study by Cedars-Sinai Medical Center has identified a drug called dasatinib that could enhance the effectiveness of immunotherapies for various types of cancers. The researchers found that combining dasatinib with anti-PD-1 therapy increased sensitivity in cancer cells, making it a promising approach to improve treatment outcomes.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers at CNIC identified a very early marker of cardiac damage in patients undergoing anthracycline therapy, allowing for early diagnosis and potential prevention of irreversible damage. The discovery has implications for patient prognosis and may lead to new therapies based on mitochondrial transplantation.
A phase 3 clinical trial found that a combination of two drugs, including an immunotherapy agent, significantly improved progression-free survival and response rates compared to a standard treatment. The results suggest that the new treatment may become a new standard for first-line treatment for patients with metastatic kidney cancer.
The open-science model is being expanded to neurodegenerative diseases such as Parkinson's and Amyotrophic Lateral Sclerosis. M4ND Pharma will pursue promising new genetic drug targets, sharing progress with the scientific community through regular online meetings.
Researchers are studying animal venoms to identify molecular targets for diseases such as osteoarthritis, rheumatoid arthritis, cancer, and neurodegenerative diseases. The study found promising antitumoral effects and potential new compounds that can be used as medicines.
A recent study published by The Endocrine Society found that oral complications are rare in women taking medications for postmenopausal osteoporosis. Despite concerns among dentists and patients, the rate of osteonecrosis of the jaw (ONJ) was low, with only 5.2 cases per 10,000 patient-years reported.
A new therapeutic target has been identified for aggressive pediatric cancers with few treatment options. The researchers discovered that malignant rhabdoid tumors may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins, and a Phase II clinical trial is underway to investigate this approach.
Researchers create 3D in vitro model capable of isolating specific metastatic cells, providing platform for identifying potential therapies and screening anticancer drugs. The model also enables study of interactions between vasculature and drugs, yielding important answers.
A UCLA-led study found that administering immunotherapy drug pembrolizumab before surgery significantly extended the lives of people with recurrent glioblastoma. The study showed that those who received the drug prior to surgery lived nearly twice as long after surgery compared to those who received it afterward.
Researchers at Karolinska Institutet develop new approach to targeted cancer treatment using Class Frizzled receptors, potentially effective against rectal and lung cancers. The study reveals molecular details of receptor activation and pathway selection.
A new cancer drug called tisotumab vedotin has shown significant promise in treating various types of cancer, with a response rate of up to 27% in patients with advanced, drug-resistant cancers. The treatment works by releasing a toxic substance to kill cancer cells from within and has manageable side effects.
Researchers at Scripps Research Institute have developed a new approach to shifting breast cancer cells into HER2-positive status using RNA-targeting precision medicines. The proof-of-concept study suggests that this technology could expand treatment options for patients with dwindling choices.
A study of 2,766 physicians found that those receiving payments from a cancer drug's manufacturer were more likely to prescribe the drug for certain types of cancer, including kidney and lung cancer. Financial relationships between physicians and drug companies can influence prescribing practices.
A multi-pronged effort will be launched to combat cervical cancer in Malawi, with a focus on early screening and same-day treatment of precancerous lesions using thermocoagulation. The project aims to increase the number of women screened and treated, and decrease loss to follow up.
A new study has identified a pair of genes that can mimic the effects of BRCA proteins, potentially making tumor cells susceptible to PARP inhibitors. The researchers found that targeting these genes could improve treatment options for people with breast or ovarian cancer caused by BRCA defects.
Researchers discovered how a metallodrug reaches cancer cells and attacks them efficiently. The molecule penetrates the cell membrane and targets essential organelles, leading to anticancer activity.
Cancer researchers have mapped oesophageal adenocarcinoma genes in unprecedented detail, unveiling more than half as potentially targetable by drugs already in trials for other cancers. This breakthrough could lead to personalized therapies and improved treatment options for patients.
Researchers at McGill University discovered a shared genetic marker that could effectively treat rare and common types of cancer, including ovarian and lung cancers. The breakthrough is based on targeting the cyclin-dependent kinases 4/6, which are vulnerable to existing drugs used in breast cancer treatment.
A recent study published in Human Reproduction found that children born after fertility treatment do not have an increased risk of developing cancer compared to those conceived naturally. However, some cancers, such as lymphoblastic leukemia and melanoma, were slightly more common in ART-conceived children, although the findings are st...
Researchers identified a crucial link between polyamines and the MYCN oncogene, revealing a new therapeutic approach to disrupt cancer cell growth. A combination therapy of DFMO and AMXT-1501 showed significant increase in survival in mice with established neuroblastoma tumours.
Scientists developed a new method to study ADP-ribosylation, a process linked to cancer growth and other diseases. The ELTA technique enables researchers to attach molecular beacons to ADP-ribose molecules, allowing for detailed studies on how this process affects cells in health and disease.
Researchers identify a new molecular pathway that suggests rapamycin, an anti-rejection medication, could be repurposed to treat certain liver cancers with β-catenin mutations. The study found that tumors are 'mTOR addicted' and can be inhibited by rapamycin, offering a precision medicine approach for improved treatment success.
A study of 28,000 childhood cancer survivors found that exposure to different anthracycline chemotherapies results in variable long-term cardiovascular risk. Specifically, daunorubicin was associated with decreased cardiomyopathy risk compared to doxorubicin, while mitoxantrone appeared to have greater long-term cardiomyopathy risk.
The Lung Cancer Master Protocol (Lung-MAP) is expanding to include patients with all types of advanced stage non-small cell lung cancers. This will allow thousands of new patients to enroll in the trial and benefit from investigational drugs, addressing a significant need for new treatments.
Drs. Silvia Formenti and Heather McArthur will collaborate on a year-long project using radiation and immunotherapy to create personalized vaccines for breast cancer patients. Their work aims to improve treatment outcomes and reduce mortality.
Scientists at CeMM Research Center have developed a method to identify promising drug combinations for chronic lymphocytic leukemia. By combining epigenetic analysis and high-throughput imaging, researchers can predict which drugs are likely to work together effectively, reducing trial-and-error approaches.
Researchers at Purdue University have developed a series of drug compounds that have shown promise in treating acute myeloid leukemia (AML), a type of blood cancer that is often lethal. The new compounds work on both common and drug-resistant forms of AML, including those with problematic mutations.
A new study found that extending medication time for varenicline to 24 weeks combined with 24 weeks of counseling sessions improves quitting success rates and reduces relapse risk in cancer patients. For those taking the medication as directed, quit rates increased significantly.
Researchers found that cancer cells switch to brute force and build a protrusion when MMP enzymes aren't available. This allows them to penetrate the basement membrane and invade other organs. The study identified a mitochondrial gene target that could be used to develop new treatments.
Shapiro's comprehensive program in early cancer drug development has provided scientific and clinical direction for multiple investigational agents. His work has contributed to the advancement of several approved drugs, including CDK4/6 inhibitors.
A new test for pediatric tumour analysis has been developed that may provide faster diagnosis times and more accurate genetic mutation detection. The test uses DNA sequencing technology to identify weaknesses in tumor cells that can be targeted with drugs, offering potential improvements in treatment options for children with cancer.
Researchers have discovered a promising new drug that targets the biological clock of cancer cells, slowing their growth and halting their spread. By disrupting the circadian rhythm of cancer cells, this drug may provide an effective new treatment option for various types of cancer.
Finasteride has been shown to reduce the risk of prostate cancer by 25 percent, with no significant increase in mortality rates. The study's findings have eliminated concerns over initial reports of potential risks, and doctors are now recommending finasteride as a preventive strategy for prostate cancer.
Researchers at University College London have discovered the genetic differences between lung cancer precursor cells and harmless lesions. This breakthrough could lead to the development of screening tests and new treatments that can stop cancer in its tracks, saving lives by detecting the disease earlier.
Researchers at University at Buffalo received an $880,000 grant to develop a model of the female reproductive tract for testing drugs delivered vaginally or to the uterus. This project aims to create cost-effective generic equivalents for existing medications, addressing the limited availability of affordable treatment options.
Researchers uncover potent and selective inhibitor of SHP2, a key target for cancer treatment. The discovery could lead to improved cancer drugs and new strategies for killing cancer cells.
SYNB1020, Synlogic's Synthetic Biotic medicine, demonstrates safety and proof of mechanism in healthy volunteers, clearing ammonia from the blood. The therapy is being evaluated in patients with cirrhosis and elevated blood ammonia, offering a potential new treatment for hyperammonemia.
Researchers at Columbia University have developed a chemical process to convert infrared light to visible energy, allowing innocuous radiation to penetrate living tissue without damaging it. This technology holds promise for enhancing the effectiveness of photodynamic therapy in treating various diseases.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
Researchers develop a novel approach to target aggressive liver cancer by inhibiting protein production, leaving healthy cells unharmed. The study shows promising results using a genetic approach and a drug that directly inhibits translation, slowing tumor growth and blocking immune evasion.
A landmark study published in the New England Journal of Medicine has found that ibrutinib is significantly more effective than standard therapy in treating CLL, causing fewer side effects and requiring less frequent patient visits. Ibrutinib was shown to improve survival rates by 13% compared to standard treatment.
A team of researchers at the University of Zurich has determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy. They found that effective drugs like EmendTM and AkynzeoTM alter the receptor's structure, allowing for long-lasting attachment and effective treatment.